Compare GameStop Corp. (GME) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs BIO-TECHNE Corp — how do they compare? GameStop Corp. trades at $25.27 (market cap $12.40B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: GameStop Corp. and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 61 Days and BIO-TECHNE Corp for 63 Days on average.
| GME | TECH | |
|---|---|---|
Market Cap | $12.40B | $11.37B |
Volume | 7,567,400 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $72.61 |
52-Week Low | $17.87 | $43.31 |
Typical Hold Time | 61 Days | 63 Days |
Enterprise Value | $11.67B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $25.28, up 2.1% on the day, with a bullish technical signal from moving averages. The company reported a net income of $131.3 million in 2025, a significant improvement from prior losses, and holds a strong cash position of $4.77 billion. Recent insider buying by CEO Ryan Cohen, including a $26.4 million purchase disclosed on September 21, 2026 (The Motley Fool), has fueled positive sentiment.
The outlook is mixed; strong cash reserves and insider confidence support upside, but declining revenue from $5.3B in 2024 to $3.8B in 2025 poses a growth risk. Analyst consensus is cautious with only 16.7% buy ratings. Key risks include execution challenges in the retail sector and high volatility typical of meme stocks.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
